Reviewer #1 (Remarks to the Author):
of Nur77 leads to only a small increase in PEPCK. It might be that the large overexpression leads to increased nuclear Nur77 and hence transcriptional activation of PEPCK. This needs to be addressed. Perhaps also use the zinc finger binding mutant in the presence of PEPCK shRNA (similar to figure 2G ). In addition, what happens to the protein and RNA expression of the other Nur77 targetes
The data on curcumin is concerning. It is unclear why it was included as it really does not add to the story and actually is quite contradictory. Numerous studies have shown that curcumin has antidiabetic, antigluconeogenic activity. This is odds with the data shown.
HepG2 are considered to be non tumorigenic. However, the authors show xenograft data with these cells using 2X106 cells. More details need to be provided as to how they were able to get these cells to form xenografts.
Huh7 in general do not express PEPCK protein (although there is abundant RNA). Therefore it is unclear how the authors were able to show PEPCK in this cell line and especially the changes observed. Indeed, in several figures, PEPCK expression is absent in these cells, eg. Supplemental figure 2F vs 2G. While the overexpression might explain some of this data, this is problematic.
According to the data, there is no PEPCK in HCC tumor tissue. Based on work done several decades ago, while perhaps decreased, there is PEPCK in liver. This is observed in the Oncomine and TCGA as well.
The authors do no discuss the use of NEM. If it is to show the sumoylation of PEPCK, why is it not used in other figures. In addition, how biologically relevant is such a small amount of sumoylation in light of the large amount of unsumoylated PEPCK. Indeed, the decreases shown in figure 3D are difficult to see, although this could be a result of such small figures (See note below regarding figures). In addition, the lower panel of figure D cannot be compared to the upper figure since Ubc and Sumo were not coexpressed. Rather anacardic acid should have been included with Sumo and Ubc9.
The experiments showing PEPCK inhibits cell proliferation should also be performed as a xenograft experiment.
Almost all the experiments showing sumoylation of PEPCK are following IP, with the exception of supplementary figure 5A and 5B, in which PEPCK was overexpressed (in a cell with PEPCK). Therefore, can the sumoylation be observed in cells without ectopic expression of PEPCK. Also can sumoylated PEPCK be observed in the absence of pulling down one of the transfected proteins. What about blotting for endogenous PEPCK vs the flag epitope with and without IP. Indeed in figure 3C , the authors A) show no change in Flag PEPCK in lysate, but also cut the blot so it cannot be determined whether there is sumoylated PEPCK in these lysates.
A more clear idea of control of PEPCK expression by Nur77 over time without CHX would be more informative (similar to figure 5A, but without CHX, not just time zero, indeed, although the blots cannot be compared since they don't look they are on the same blot, it does not look like there is a difference or if anything, PEPCK levels seem lower in cells with Nur77 at time 0.
Other issues:
Reviewing the manuscript was very difficult since the size of the figures was so small. In addition, the manuscript is need of significant copy editing.
A number of statements that are made are overly stated Eg. "anacardic acid markedly stimulated..." there was a small change-not markedly.
It is unclear how the authors can make the statement on line 215. Both ALLN and MG132 will inhibit proteosomal degradation. Therefore, this raises the questions as to how ALLN did not have a similar effect as MG132.
Reviewer #2 (Remarks to the Author):
In the here present study authors evaluate importance of the nuclear receptor Nur77 and PEPCK1 enzyme as potential tumor suppressors in hepatocellular carcinoma (HCC) . By utilizing different approaches and models (in vitro, in vivo, human samples) the authors aim to explore the effects of Nur77 downregulation on HCC development. Further, they delineate a new regulatory role for Nur77 for PEPCK1 sumoylation and subsequent ubiquitination.
Key findings: -Majority of the HCC patients show downregulation of Nur77 in the tumor tissue compared to the normal liver. Patient expressing low amount of Nur77 have close association with poor clinical prognosis.
-Increased level of Nur77 induces tumor suppressive effect in HCC by promoting gluconeogenesis, preventing glucose uptake and depleting intracellular ATP.
-Nur77 prevents sumoylation and degradation of PEPCK1, a rate-limiting enzyme of gluconeogenesis. Stability of PEPCK1 is dependent on sumoylation of Lys124.
-Curcumin induces Nur77 gene and protein upregulation and, therefore, promotes antitumorigenic properties.
-Snail transcription factor is suppressing Nur77 gene expression by binding to E-boxes on Nur77 promoter.
Overall, the study focuses on an important topic, namely the relevance of key regulators of gluconeogenesis for hepatocarcinogenesis. The study is technically well performed. However, some of the mechanistic findings need to be extended and utilized cell lines should be consistently applied across the experiments. A potential p53-dependent role should further be explored (Zhang et al. PNAS 2014) . Major comments -Given the impact of PEPCK1 on T-cell function (Ho et al. Cell 2015) and the importance of the chronic inflammatory liver disease for HCC development, pre-neoplastic stages of hepatocarcinogenesis should be explored in the context of the here suggested study. Further, clinic-pathological information for the investigated specimens should be added. Further, the data for the Nur77 expression in the investigated HCC cohort should be shown. -Throughout the manuscript the utilized of cell lines are inconsistently applied (e.g. Figure 1 and 2). This should be extended, in particular for the investigation where only hepatoma cell line (and 293T cells) was used (e.g. Figure 4 ). Further, it would be interesting to include untransformed hepatocytes as a negative control. Furthermore, given the dominant role of p53 (also suggested in the introduction) on gluconeogenesis and the high incidence of p53 mutations in HCC, it might be interesting to explore this issue. This could be achieved, e.g. by adding the p53-null cell line Hep3B. Of note, SK-Hep1 is a cell line of endothelial origin (Heffelfinger et al. 1992 ) and should not be used synonymously in the context with HCC cell line. The cell line should be replaced.
-The authors suggest a direct regulatory effect of Nur77 on PEPCK1 (Supplemental Figure 2) . While this is certainly interesting, mechanistic investigations confirming the suggested direct regulatory effect are missing. This should be extended to confirm the Nur77-PEPCK1 regulatory role for HCC. Further, despite the potential regulation of PEPCK1 it remains unclear how Nur77 affects the tumorigenic potential of HCC cells, e.g. by regulating WNT signaling (Chen et al. Gut 2012) . In line with this, impact of Nur77 on sumoylation and the suggested mechanism of operation are not striking and most pronounced in non-hepatoma 293T cells ( Figure 5 ). Quantification and statistical evaluation is needed. Similar, statistical analyses of (e.g. Supplemental Figure 5A ) seem necessary, since different base line levels of PEPCK1 expression are shown. -Given the plethora of different curcumin targets, the mechanisms of Nur77 upregulation by curcumin are unclear and should be evaluated. Since curcumin is known to inhibit cell growth of hepatoma cells by affecting multiple molecular targets, specificity for the suggested findings should be confirmed by a more targeted approach.
-Promotor methylation of Nur77 should be confirmed in the cell lines ( Figure 6 ). Rational for Snail selection should be explained in more detail.
Minor comments -The study by Wurmbach et al. includes 4 stages of HCC. Please explain the differences in the here presented study. Please also explain how the statistical analyses shown in the Figure have been derived. -The effect of different Nur77 levels on proliferative status in individual tumors (e.g. by Ki67 and PCNA) should be confirmed. -The authors suggest that Nur77 is driven by non-genomic events. Please extend the explanation of this hypothesis. Maybe data supporting that Nur77 is not impaired by genetic alterations (e.g. by using publically available repositories) can be included. -It is unclear how the doses for the used compounds were established in the respective cell lines. Experimental data or suitable references should be provided. -Number of replicates and statistical analyses should be added wherever necessary.
Reviewer #3 (Remarks to the Author):
Bian et al's manuscript demonstrates how Nur77 as a tumor suppressor suppresses hepatocellular carcinoma. They show that Nur77 is a tumor suppressor of HCC and affects gluconeogenesis via interacting with PEPCK1. They also show that PEPCK1 is a SUMOylated protein and SUMOylation affects PEPCK1 stability. More interestingly, they find that p300 enhances PEPCK1 sumoylation through acetylating UBC9. Increasing Nur77 expression by compound curcumin could suppress PEPCK1 sumoylation and HCC. This manuscript is quite complicated but of interesting, especially they find that p300 acetylation of UBC9 enhances PEPCK1 sumoylation, which will be a novel regulation mechanism for sumoylation.
Major: 1. Authors showed that sumoylation down-regulated PEPCK1 stability, which would decrease gluconeogenesis and increase tumorgenesis in HCC. If it is true, it should be detected that PEPCK1 is highly-sumoylated in HCC samples compared to in normal liver tissue, which would strongly support the link between PEPCK1 SUMOylation and tumor suppressor function of Nur 77. Additionally, how sumoylation affect PEPCK1 stability? 2. It has been shown that sumoylation of PEPCK1 decreases tumorigenesis in HCC. Therefore, sumoylation mutant of PEPCK1 would rescue the tumorigenesis in Nur77-silenced HCC. They should do that to conclusively make statement that Nur 77 suppress HCC via PEPCK1 sumoylation.
3. It is of interesting that p300 acetylation UBC9 increases PEPCK1 sumoylation. Does p300-UBC9 regulation affect global sumoylation? It seems that acetylated UBC9 has more affinity to bind to PEPCK1 than un-acetylated form. They should prove it by binding experiment. 4. The authors mention that hepatic expression of Nur77 can elevate gluconeogenesis through transcriptional upregulation of gluconeogenic genes, including G6pc, Fbp1 and Fbp2, and Eno317. They also show that mutation of Nur77 binding to DNA affect the growth of SMMC-7721 cells (Supplemental Figure 2B) , suggesting that the transcription activity of Nur77 also engage the tumorigenesis. How to comment the contribution of Nur77-PEPCK1 non-transcription activity and Nur77 transcription activity to HCC? Minor: 1. In Fig 3a, Is there any changes in PEPCK1 sumoylation in liver with or without DEN/CCL4 treatment? 2. In Fig 4 , Does knock-down p300 affect PEPCK1 expression as well as sumoylation in HCC cells? 3. In Fig 4a (bottom) , overexpression of p300 decreased endogenous PECPK1 expression in 293T and HepG2, did affect the sumoylation of endogenous PEPCK1? 4. The author mentioned in the discussion that the third mechanism of Nur77 regulating PEPCK1 is attenuating p300-induced PEPCK1 acetylation, is there any evidence for it? 2788-96), the following results indicated that insulin or IGF signaling was not involved in Nur77-mediated HCC suppression. In the DEN/CCl4 model, Nur77-KO mice developed HCC at a higher rate than WT mice; however, insulin and IGF1 levels were equal between these groups of mice ( Supplementary Fig. 1h ). Similarly, in the HFD/STZ model, in which mice were intraperitoneally injected with the β cell toxin streptozotocin (STZ) at 2 days of age, the insulin and IGF1 levels in Nur77-KO mice were also comparable with those in WT mice ( Supplementary Fig. 1h ), unlike the reported HFD model (i.e., no injection with STZ. . 2009; 58(12): 2788-96) . Together, our results suggest that Nur77 suppresses HCC independent of insulin or IGF1. To answer the question of "What about endogenous PEPCK under conditions of increased sumoylation," we added an experiment using HepG2 cells, in which the endogenous sumoylation of PEPCK1 could also be detected in the presence of NEM, an inhibitor of de-sumoylation (Figure 3c ). NEM was thus used to detect PEPCK1 sumoylation hereafter. We further verified that in different HCC cell lines, increased endogenous sumoylation of PEPCK1 by transfection of p300 was associated with decreased endogenous PEPCK1 protein level (Figure 4b ). In clinical HCC samples, increased sumoylation accompanied decreased PEPCK1. Conversely, there is no sumoylation, but high PEPCK1 levels, in para-carcinoma samples ( Figure 3b ). Thus, higher sumoylation indeed corresponds to lower endogenous PEPCK1 levels in vivo.
Previous studies using

Diabetes
The authors need to show
In our study, PEPCK1 sumoylation promoted its ubiquitin-proteasomal degradation (Figure 3h ), suggesting that endogenous sumoylated PEPCK1 is more labile and difficult to detect without immunoprecipitation.
Unlike other modifications, such as ubiquitination, sumoylation is described as "low-level, big-effect." Few proteins are quantitatively sumoylated, either constitutively or upon receiving their respective upstream signals (J. Proteome Res. 2015 Res. , 14:2385 . Instead, most targets appear to be modified to a small percentage at steady state. However, the fact that a small pool of sumoylated protein causes the dramatic effects that have been assigned to sumoylation has been well recognized (EMBO J. 2002 (EMBO J. , 21:1456 Mol. Cell. 2003 , 11:1043 -1054 Mol. Cell. 2006, 24:341-354) . As Ruth Geiss-Friedlander and Frauke Melchior mentioned in their review (Nature Reviews Molecular Cell Biology. 2007, 8:947-956) , sumoylated targets can undergo rapid cycles of modification and demodification.
Although this equilibrium might lie on the side of the unmodified form, the whole pool of a given protein might be affected by sumoylation in a short window of time (Cell Metabolism. 2014, 20: 603-613) . For example, steady-state sumoylation is usually less than 5%, and most transcription factors and co-regulators become significantly activated when the SUMO acceptor Lys residue has been mutated to an Arg residue (Mol. Cell. 2014, 13: 611-617) .
Therefore, in most reports, the sumoylation level (particularly the endogenous level) is lower, but its outcomes are extremely diverse and important, including the localization of proteins and the activities of enzymes and target proteins. Figure 2d) . In addition, both Nur77 (Figure 2i ) and Nur77 2G (Supplemental Figure 2p) efficiently inhibited clone formation in the control group, but not in PEPCK1-KD Huh7 cells. Together, these results further demonstrate that Nur77 has an effect on cell proliferation through PEPCK1 mediation that is independent of its transcriptional activity.
9. The data on curcumin is concerning. It is unclear why it was included as it really does not add to the story and actually is quite contradictory. Numerous studies have shown that curcumin has antidiabetic, antigluconeogenic activity. This is odds with the data shown.
Curcumin has various activities, including anticancer, antidiabetic, and antigluconeogenic activity. However, its mechanism of action is very complex. Based on the questions from you and Reviewer #2, the Editor has suggested deleting all of the curcumin data from the manuscript. We agree with this suggestion.
10. HepG2 are considered to be non tumorigenic. However, the authors show xenograft data with these cells using 2X106 cells. More details need to be provided as to how they were able to get these cells to form xenografts.
In the ATCC catalog, the HepG2 cell line is reported to be non-tumorigenic; however, NEM is an inhibitor of de-sumoylation. Because sumoylated targets can undergo rapid cycles of modification and demodification, NEM was used in all sumoylation assays described in the Methods section (Page 6 in Supplementary information). To avoid confusion, we have revised Supplementary Figure 3a ( original Figure 3c) and also now describe its role in the Result section (page 11).
With regard to the question "such a small amount of sumoylation in light of the large amount of unsumoylated PEPCK," please see our previous explanation. Such phenotypes of lower sumoylation have also been observed in other reports (Cancer Cell. 2014, 25:748-761; Cell. 2007, 131:584-595) . In particularly, the sumoylated PEPCK1 was more labile and was degraded by the ubiquitination pathway. Thus, sumoylated PEPCK1 is difficult to detect.
According to the suggestion, we performed a new experiment in which Sumo and Ubc9 were first transfected into different cell lines as indicated, and then, cells were treated with anacardic acid. As expected, anacardic acid treatment obviously increased endogenous PEPCK1 expression levels (Figure 3d, bottom) . This result, together with the data in Figure   3d (middle), suggested that inhibition of both endogenous and Sumo/UBC9 overexpression-induced PEPCK1 sumoylation efficiently influenced PEPCK1 protein levels.
14. The experiments showing PEPCK inhibits cell proliferation should also be performed as a xenograft experiment.
Thank you for your suggestion. We have performed this xenograft experiment. As shown in Figure 2f , PEPCK1 overexpression significantly repressed xenograft tumor growth, and PCNA and Ki67 expression were also repressed in the xenograft tumor of PEPCK1 transfection (Figure 2g expression. As mentioned previously, the sumoylated form of PEPCK1 is substantially more labile, so it is very difficult to detected endogenous PEPCK1 sumoylation in the absence of pulling down PEPCK1 or SUMO1.
The expression level of exogenous Flag-PEPCK1 is substantially stronger than that of endogenous PEPCK1, as revealed using an anti-PEPCK1 antibody (shown below).
Overexpression of UBC9 and SUMO1 enhances Flag-PEPCK1 sumoylation, which is easy to detect without IP, as shown in Supplementary Figure 3b According to your suggestion, we now include a whole image in Figure 3c (now presented in Supplementary Figure 3a) , in which the sumoylated PEPCK1 could also be observed in cell lysates. We agree with your viewpoint that "control of PEPCK expression by Nur77 over time without CHX would be more informative." To this end, we performed an experiment in which SUMO/Ubc9 and Nur77 were transfected together into cells, and we analyzed PEPCK levels at different times without CHX treatment. The result indicated that endogenous PEPCK1 levels could be elevated by Nur77 at different Nur77 transfection times (Figure 5c ). Thus, PEPCK1 expression can be regulated by Nur77.
As you mentioned, the results in Supplementary Figure 5c We apologize for mistakenly labeling "ALLM" as "ALLN." The compounds we used in Figure 3h were MG132 and ALLM. ALLM is a calpain inhibitor, while MG132 is a proteasome inhibitor. Thank you for your suggestion. To display the pre-neoplastic stages of hepatocarcinogenesis, we detected hepatic cirrhosis in DEN/CCl4-induced HCC mouse samples by PicroSirius Red staining, which showed that more hepatic fibrosis was detected in Nur77-KO mice than in WT mice (Supplemental Figure 1c) . Consistently, Nur77-KO mice also developed more severe inflammatory status in this DEN/CCl4 model, as indicated by higher circulating IL-6 levels (Supplemental Figure 1d) . Because inflammation and cirrhosis are considered major risk factors for hepatocarcinogenesis, our results suggested that Nur77 not only inhibits HCC development but also retards HCC initiation.
Responses to Reviewer #2
The clinic-pathological information and Nur77 immunoreactive scores in the investigated specimens are shown in Supplemental Table 2 . In this manuscript, we mainly used HepG2 (higher Nur77 expression), SMMC-7721 and Huh7 (lower Nur77 expression) to analyze the biological functions of Nur77 and its effects on PEPCK1. 293T cells were mainly used for transfections due to their higher transfection efficiency. To make the utilized cell lines consistent, we added some critical experiments in hepatoma cell lines in Figure 1f , 3d, 4b, 5a and Supplementary Figure 2b , 2d, 3d, 4a, 4e in the revised version.
According to the suggestion, we also tested the functions of Nur77 in untransformed hepatocyte L02 cells. However, we unexpectedly found that in L02 cells, Nur77 was mainly in the nucleus (Supplemental Figure 2d) . L02 cells displayed a resistance to Nur77-mediated repression of cell proliferation (Supplemental Figure 1k) , although Nur77 showed similar regulatory effects on glucose metabolism in L02 cells (Supplemental Figure 2c) as in liver cancer cells (Figure 2a, bottom) . In addition, Nur77 overexpression regulated the expression of its target gene E2F1 in L02 cells but not in liver cancer cell lines (Supplementary Figure   2e) . These results suggest that the Nur77 regulatory mechanism in L02 cells is different from that in liver cancer cells.
A p53-null cell line Hep3B was used to analyze the p53 role in the current study. The results indicated that Nur77 overexpression still inhibited clone formation and regulated gluconeogenesis (Supplemental Figure 1m & 2b) , similar to the effects observed in the HepG2 cell line (WT p53 expression). Therefore, Nur77 exerted its functions independent of p53 in our study.
According to the suggestion, we deleted the SK-Hep1 cell line and added three additional liver cancer cell lines in the revised version of the manuscript (Supplemental Figure 1i) . To confirm the Nur77-PEPCK1 regulatory role for HCC, we performed colony-formation assays, which showed that Nur77 and Nur77 2G only inhibited colony formation in controls, but not PEPCK1-knockdown HCC cells (Figure 2i , Supplementary   Figure 2p) , suggesting a role of PEPCK1 mediation. Furthermore, the xenograft tumor assay in nude mice showed that Nur77 substantially inhibited the PEPCK1-expressing xenograft tumor growth, but slightly influenced the PEPCK1 K124R-expressing tumor growth (Figure   5f ), further emphasizing that the Nur77 repression of HCC depends on the sumoylation of PEPCK1 at Lys124.
3-The authors suggest a direct regulatory effect of Nur77 on PEPCK1 (Supplemental
To determine whether Nur77 also inhibits Wnt signaling to retard HCC growth, the plasmid dnTCF4, which has been shown to inhibit Wnt signaling activity (Mol Cell Biol. 1999; 19(8):5696-706) , was constructed. Nur77 could efficiently inhibit cell proliferation in both wildtype HCC cells and Wnt signaling-inactivated HCC cells that were transfected with dnTCF4 ( Supplementary Figure 1l) , suggesting that Wnt signaling is not required for Nur77 to inhibit HCC in our study.
In this version, we deleted some of the experiments performed in 293T cells and supplemented additional experiments using HCC cell lines, including Figures 3c, 3d, 4b, 5a and 5c.
Necessary quantification and statistical evaluations have been included in Figure 3E Curcumin has multiple molecular targets to exert its functions, and its functions in cancer are complex. According to the comments from you and Reviewer #1, the Editor has suggested deleting the content of the curcumin study. We agree with this suggestion.
5-Promotor methylation of Nur77 should be confirmed in the cell lines (Figure 6).
Rational for Snail selection should be explained in more detail.
We added additional experiments to detect Nur77 promoter methylation in different HCC cell lines (Figure 6b , bottom).
Snail is a suppressive transcription factor that binds to E-box DNA sequences to silence gene expression through the recruitment of chromatin remodelers and DNA methyltransferases (Nat Rev Mol Cell Biol. 2014; 15(3):178-196; The Journal of clinical investigation 2012 , 122(4): 1469 -1486 Cancer cell 2013, 23(3): 316-331) . Snail-mediated epigenetic regulation was recently reported to be involved in hepatocarcinogenesis (Cell Death Differ. 2016; 23(4):616-27) . After sequence analysis, we found at least five Snail-binding E-boxes (CAGGTG) in the proximal region of the Nur77 promoter (Supplementary Figure 6a) , indicating that Snail may be involved in the epigenetic regulation of Nur77 in HCC. We have rewritten the Snail-associated paragraph on page 17. Supplementary Fig. 1a .
Significance was determined with one-way ANOVA followed by Tukey's post hoc test.
7-The effect of different Nur77 levels on proliferative status in individual tumors (e.g. by
Ki67 and PCNA) should be confirmed.
To confirm the effect of different Nur77 levels on proliferative status, we analyzed PCNA protein levels in clinical samples. As expected, Nur77 and PCNA protein showed a clear negative correlation (Supplemental Figure 1b) .
8-The authors suggest that
Nur77 is driven by non-genomic events. Please extend the explanation of this hypothesis. Maybe data supporting that Nur77 is not impaired by genetic alterations (e.g. by using publically available repositories) can be included.
Nur77 not only acts as a transcription factor to positively or negatively regulate downstream gene expressions but also performs its non-genomic actions independent of its regulation of downstream target genes. This functional mode of Nur77 has been demonstrated recently by several reviews (Steroids. 2015 Mar; 95:1-6; Expert Opin Ther Targets. 2012; 16(6):573-85) . In this study, we showed that Nur77 could not influence the transcription level of PEPCK1 (Supplementary Figure 5b) , and Nur77 2G, a Nur77 mutant without transcriptional activity, could still inhibit HCC growth (Supplementary Figure 2f & 2p) . These results suggested that transcriptional activity is not involved in Nur77 inhibition of HCC. According to the suggestion, we added two in vivo sumoylation detection assays in clinical and mouse samples. In clinical para-carcinoma samples, PEPCK1 expression was higher than in carcinoma samples, while its sumoylation could be hardly detected in para-carcinoma samples (Figure 3b) . In mouse samples, sumoylation was detected in DEN/CCl4-induced HCC samples, but not in normal liver tissues ( Figure 3a) . As Nur77 expression was lower in carcinoma samples but higher in para-carcinoma samples (Figure 1a) , and as Nur77 and PEPCK1 showed a positive correlation (Figure 2c ), these results strongly support the link between PEPCK1 sumoylation and the tumor suppressor function of Nur77.
Moreover, the fact that Nur77 efficiently inhibited xenograft tumor growth when wildtype PEPCK1 was co-expressed, but only moderately inhibited tumor growth when PEPCK1 K124R was co-expressed (Figure 5f ), further confirmed the suppressive function of Nur77 on HCC relied on its regulation of PEPCK1 sumoylation.
Our results indicated that sumoylation affects PEPCK1 stability through the ubiquitin-proteasome pathway, as MG132 but not ALLM treatment led to PEPCK1 accumulation in the presence of SUMO1/Ubc9 (Figure 3h, left) , which was accompanied by increased endogenous ubiquitin targeting to PEPCK1 but not to PEPCK1 K124R (Figure 3h , middle). For comparison, increased ubiquitination was still detected on PEPCK1 K471&473R (Figure 3h , right), which is another indication that Lys124 is the only critical sumoylation site for PEPCK1 stability.
It has been shown that sumoylation of PEPCK1 decreases tumorigenesis in HCC.
Therefore, sumoylation mutant of PEPCK1 would rescue the tumorigenesis in Nur77-silenced HCC. They should do that to conclusively make statement that Nur 77 suppress HCC via PEPCK1 sumoylation.
To further verify Nur77 repression in HCC via PEPCK1 sumoylation, we performed xenograft experiments in nude mice. As shown in Figure 5f , Nur77 efficiently inhibited PEPCK1-expressed xenograft tumor growth, but only slightly influenced PEPCK1
K124R-expressed tumor growth, further suggesting that Nur77 suppressed HCC via regulation of HCC PEPCK1 sumoylation at Lys124.
3. It is of interesting that p300 acetylation UBC9 increases PEPCK1 sumoylation. Does p300-UBC9 regulation affect global sumoylation? It seems that acetylated UBC9 has more affinity to bind to PEPCK1 than un-acetylated form. They should prove it by binding experiment.
According to your suggestion, we detected global sumoylation in several HCC cells, and the results indicated that transfection of p300 could not affect the global sumoylation induced by Ubc9 (Supplemental Figure 4e ). It appears that p300-mediated Ubc9 acetylation selectively influences PEPCK1 sumoylation.
The acetylation of Ubc9 at Lys65 by p300 facilitates its binding with PEPCK1, as revealed in Figure 4e , in which the transfection of p300 enhanced the PEPCK1-Ubc9
interaction, but not the PEPCK1-Ubc9 K65R interaction. However, PEPCK1 interacted with both Ubc9 and its mutant Ubc9 K65R with similar affinity (Supplemental Figure 4g ) without the presence of p300, which further indicates that p300, through acetylating Ubc9 and facilitating acetylated Ubc9 binding to PEPCK1, could enhance PEPCK1 sumoylation. We have added this experiment. In mouse liver samples, sumoylation could be detected in DEN/CCl4-induced HCC, but not in normal liver tissues (Figure 3a ).
In Fig 4, Does knock-down p300 affect PEPCK1 expression as well as sumoylation in HCC cells?
As shown in Supplementary Figure 4a , knockdown of p300 did affect PEPCK1 expression or sumoylation in transfection or endogenous experiments in different HCC cell lines.
6. In Fig 4a (bottom) , overexpression of p300 decreased endogenous PECPK1 expression in 293T and HepG2, did affect the sumoylation of endogenous PEPCK1?
Overexpression of p300 increased endogenous PEPCK1 sumoylation, accompanied by decreased endogenous PEPCK1 expression, in different HCC cell lines (now presented in Figure 4b ).
7. The author mentioned in the discussion that the third mechanism of Nur77 regulating
